Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Andreas Ritzén; Jesper Mosolff Mathiesen; Christian Thomsen

doi:10.1111/j.1742-7843.2005.pto_156.x

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Andreas Ritzén, Jesper Mosolff Mathiesen, Christian Thomsen^*

^*Corresponding author af dette arbejde

Det Juridiske Fakultet

90 Citationer (Scopus)

Abstract

The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

Originalsprog	Engelsk
Tidsskrift	Basic and Clinical Pharmacology and Toxicology
Vol/bind	97
Udgave nummer	4
Sider (fra-til)	202-213
Antal sider	12
ISSN	1742-7835
DOI	https://doi.org/10.1111/j.1742-7843.2005.pto_156.x
Status	Udgivet - 1 okt. 2005

Adgang til dokumentet

10.1111/j.1742-7843.2005.pto_156.x

Andre filer og links

Link to publication in Scopus

Citationsformater

@misc{9d4da19609c6466cab97f6e8c0c67c18,

title = "Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators",

abstract = "The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.",

author = "Andreas Ritz{\'e}n and Mathiesen, {Jesper Mosolff} and Christian Thomsen",

year = "2005",

month = oct,

day = "1",

doi = "10.1111/j.1742-7843.2005.pto_156.x",

language = "English",

volume = "97",

pages = "202--213",

journal = "Basic & Clinical Pharmacology & Toxicology Online",

issn = "1742-7843",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - GEN

T1 - Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

AU - Ritzén, Andreas

AU - Mathiesen, Jesper Mosolff

AU - Thomsen, Christian

PY - 2005/10/1

Y1 - 2005/10/1

N2 - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

AB - The metabotropic glutamate receptors (mGluR) consist of a family of eight G-protein-coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.

UR - http://www.scopus.com/inward/record.url?scp=26444616159&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2005.pto_156.x

DO - 10.1111/j.1742-7843.2005.pto_156.x

M3 - Short survey

C2 - 16176554

AN - SCOPUS:26444616159

SN - 1742-7843

VL - 97

SP - 202

EP - 213

JO - Basic & Clinical Pharmacology & Toxicology Online

JF - Basic & Clinical Pharmacology & Toxicology Online

IS - 4

ER -

Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater